Mawdsleys Specialty Pharma (MSP) partners with Pharma & Biotech companies to deliver pre-license named patient programmes, registration and commercialisation of pharma products.
Product licensing: we offer a full turnkey product registration and market access service for pharmaceutical and biotech companies in our core territories of UK, Brazil and Israel.
Named Patient Programmes: working with pharmaceutical companies and healthcare providers, to provide physicians and patients access (in accordance with regulatory requirements) to medicines not approved in their home country, through a fully managed offering.
to over 1,000 hospitals
in 6 continents each year
Named Patient Programmes
delivered into 47 countries
including 21 of EU 27
80+ Pharma &
3 Global Offices
Product Licensing, Market Access and Named Patient Supply Delivered through our 3 Global Offices
Pharma Healthcare Service
Provider with a 200 year history
Founded in 1825, Mawdsleys is the largest independent supplier of both unlicensed and licensed medicines to the National Health Service. Mawdsleys has expanded its global presence with operations in Brazil and Israel and continues to develop into new territories internationally.
We have expertise in all areas of the pharmaceutical supply chain, from providing physicians and their patients access to unlicensed medicines and third party distribution, to in-licensing products in territories. Our global infrastructure and expertise in country-specific regulatory systems mean we are ideally placed to ensure patients all over the world get the medicines they need, when they need them.
Niche Pharmaceuticals and Rare Genetic Diseases are our fields of expertise.
Rare diseases affect a very small percentage of each population in a country, but most are associated with life-long disability, often starting in childhood. Many of these rare diseases are chronic, degenerative and potentially life-threatening conditions, often under-diagnosed or diagnosed too late. A supportive, dedicated framework has been set up in the USA, EMA and many others geographies to promote a greater understanding of these diseases, stimulate more public and private research and to encourage innovative biopharma companies to develop and make available breakthrough treatments for some of these diseases.
Access to these products can be complex, challenging and costly. For over 15 years, Mawdsleys has been the reference partner for many physicians and their patients to source the products patients need as quickly as possible whilst ensuring compliance with regulatory systems. With its well-established Unlicensed Medicines organisation in more than 52 countries (including Europe, Brazil, Israel), Mawdsleys Specialty Pharma has the expertise and resource to source niche medicines that are not licensed or readily available for the patients suffering from these rare diseases. In many cases, Mawdsleys Specialty Pharma is also able to help patients access funding for these important but costly medicines.
Countries we supply, source
and licence medicines for
Strictly Necessary Cookies
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.